Skip to Content
Last Updated: 04/25/2012

Definitive, Late Phase Trials

Trial Assessing Individualized Options for Treatment in the Adjuvant Setting for Women with Breast Cancer

The Trial Assessing Individualized Options for Treatment (TAILORx), an ongoing randomized clinical trial, is testing the benefit of adjuvant chemotherapy in women with early stage breast cancer selected using a molecular profiling assay.

Prior studies have validated that Oncotype DX®, a molecular profiling test that analyzes the expression of a 21-gene panel in biopsy samples from women with estrogen-dependent, lymph-node negative breast cancer, can predict the risk of breast cancer recurrence. The studies also appear to identify which of those patients will benefit most from chemotherapy. Currently, chemotherapy is recommended for most women with this type of breast cancer, many of whom may be adequately treated with hormone therapy alone. The NCI-sponsored Cooperative Groups are conducting TAILORx to determine whether hormonal therapy alone is inferior to the standard of chemotherapy plus hormonal therapy in women with estrogen-dependent, lymph-node negative breast cancer. TAILORx closed to accrual in October 2010 after completing its target enrollment of 10,273 patients. The results of this study could potentially show that many women can be spared the short- and long-term toxic effects and costs of chemotherapy each year.

About the
Associate Director

Jeffrey S. Abrams, M.D. Jeffrey S. Abrams, M.D., has led the Cancer Therapy Evaluation Program (CTEP) since June 2007.  Dr. Abrams came to CTEP in 1993 when he joined as a clinical research scientist to oversee the breast cancer treatment trials portfolio and participate in clinical trials at the NIH Clinical Center and the National Naval Medical Center. More…

For More Details
About CTEP